There are many mechanisms underlying the hypertension which occurs after thoracic transplantation. Previous disease, effects of cyclosporin, tacrolimus and steroid immunosuppression and cardiac denervation are major contributory factors. Abnormal sodium and water balance is an important common mediating factor. A new approach is clearly needed for classifying the severity of hypertension in these patients taking into account day-night variation and total blood pressure
Introduction
Transplantation is an important option for patients suffering from end-stage heart and/or lung disease. Over 40 000 heart, 2100 heart-lung, 3900 single lung and 2500 double lung transplant procedures were performed worldwide to 1997 in a total of nearly 300 centres. 1 End-stage heart failure is an increasing cause of morbidity, mortality and a burdensome public health expenditure in the developed world. There have been major recent improvements in the medical management of heart failure largely as a result of successful trials of angiotensin-converting enzyme (ACE)-inhibitor treatment. These have been shown to cause a marked slowing in the rate of disease progression [2] [3] [4] [5] and the unexpected additional benefit of a reduced rate of myocardial infarction in patients with ischaemic heart disease. 5 However, the mortality rate in heart failure remains higher than for many malignancies and, in the absence of a reversible cause, heart transplantation is the only curative treatment available.
Cardiac transplantation is now a well-established treatment for end-stage cardiac failure. Longer recipient survival, approaching 50% at 10 years after heart transplantation, 1 and greater experience in larger transplant centres has led to the recognition that a number of new medical problems may develop after transplant 6, 7 : hypertension, ischaemic heart disease as a result of occlusive disease in the transplanted coronary arteries, chronic transplant rejection leading to direct immunological damage to the muscle of the transplanted heart; renal disease Correspondence: Dr Donald RJ Singer, Heart Science Centre, National Heart and Lung Institute, Imperial College School of Medicine, Harefield Hospital, Harefield, Middlesex UB9 6JH, UK (BP) load. This would allow improved strategies for investigation and treatment. The evidence suggests that ambulatory BP measurements should be included in the assessment of initial severity of post-transplant hypertension as well as response to treatment. Further studies are needed to look at the effects of raised clinic and 24-h ambulatory BP and its treatment on longer term morbidity and mortality in thoracic transplant patients.
complicating effective immunosuppression with cyclosporin A, late opportunistic infections, osteoporosis 8 and malignancies. The aim of this review is to discuss hypertension and its complications after thoracic transplantation. The majority of published work related to hypertension after cardiac transplantation. Better understanding of post-transplant hypertension is clearly potentially relevant to reducing transplant coronary artery disease and vascular disease at other sites, preserving myocardial function and limiting progression of renal disease. The reader's attention is drawn to other comprehensive reviews focusing on different aspects of post-transplant hypertension.
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Prevalence of hypertension
Hypertension is very common following transplantation 14, 15 and the prevalence increases further with time after transplant. 16 The registry of the International Society for Heart and Lung transplantation reported a prevalence of 65% at 1 year and 67% by 2 years following heart transplantation, and a lower incidence of 44% at 1 year and 57% at 2 years following lung transplantation. 1 Baroud and colleagues 17 found a prevalence of hypertension of 67% at 5 years in 60 cardiac recipients. This compares to a prevalence of 45% in a cohort of liver transplant recipients. 18 The largest single series is of 488 heart transplants; a cumulative prevalence of 52% for hypertension was reported at 1 year and 77% by 4 years after transplant. 16 For the great majority of patients in this study, immunosuppression was similar to current management. Cyclosporin A was the mainstay of immunosuppression in all but 39 transplant recipients and hypertension prevalence was similar in those on low compared with higher dose cyclo-sporin treatment. There was an age effect with a lower initial and reduced longer term prevalence in recipients under the age of 21. The prevalence of post-transplant hypertension was greater in men than women, however this may have been confounded in part by differences in underlying heart disease, as cardiomyopathy is relatively more common in women than in men as a reason for transplantation. A follow-up study of 275 cardiac transplant recipients showed that those transplanted for coronary artery disease had more severe hypertension when compared to those transplanted for cardiomyopathy. 19 The above findings provide some clues to possible underlying mechanisms.
Initiation and amplification
The natural history of post-transplant hypertension is strikingly reminiscent of Barker's hypothesis that events in utero can lead to increased levels of blood pressure (BP) and cardiovascular disease in later life through amplification of earlier structural or functional cardiovascular abnormalities. 20 Pre-transplant BP appears to have an important bearing on the likelihood of developing hypertension with time after transplant. Younger patients and those with nonischaemic reasons for transplantation start with a reduced frequency of hypertension, and are also less likely to go on to develop hypertension. 16 This suggests that initiating factors may have an important influence on the later prevalence of hypertension in transplant patients. This also suggests that if these initiating mechanisms can be identified and removed or reduced, then later hypertension may be prevented. Thus a key strategy in understanding post-transplant hypertension needs a dual approach with identification both of initiating and potentiating factors.
Significance of pre-transplant hypertension
The typical patient presenting for cardiac transplantation is in end-stage heart failure, has a low cardiac output and is often hypotensive. When an improved cardiac pump is provided by the donor heart and cardiac output increases towards normal, pre-existing hypertension may then be revealed. There are several important clues for the role of pre-transplant hypertension in the aetiology of post-transplant hypertension. It is more common in patients with a previous family history of hypertension and/or its major cardiovascular complications, myocardial infarction and stroke. 16 It is also more frequent in older patients and in men and there is a trend for a higher prevalence of hypertension in patients with preceding ischaemic heart disease. 16 The increased prevalence in older transplants may be in part explained by differences in the cause of heart failure as these patients are more likely to have been transplanted because of ischaemic heart disease. Patients with ischaemic causes have a relatively higher early and increased later frequency of hypertension after transplant (57% at 1 year; 77% at 3 years) compared with patients with other preceding causes of heart disease (45% at 1 year; 67% at 3 years), 16 and their hypertension is more severe. 19 Data from the Framingham study over more than three decades of follow-up showed that 76% of men and 79% of women presenting in heart failure were hypertensive or had been taking antihypertensive medication previously. 21 This may be an overestimate of hypertension as a risk factor for heart failure based on a review of the more recent studies of ACEinhibitors for heart failure in which the frequency of previous hypertension has been lower, although still very common at, eg, 42-44% in the SAVE trial 5 and 36-37% in SOLVD. 3 The rule of halves still holds for hypertension: around half the population who do have high BP are still likely to be undiagnosed. Thus the true prevalence of pre-existing hypertension is likely to lie between that of the Framingham study 21 and the estimates from the ACE-inhibitor studies. 3, 5 The above may in part explain the increased prevalence of hypertension in heart when compared with lung transplant recipients.
Abnormal nocturnal BP fall in transplant recipients
In essential hypertension, elevated 24-h ambulatory BP is a predictor of cardiovascular risk. 22 There are no large scale studies looking at the prognostic value of ambulatory BP monitoring following transplantation.
In normal subjects, there is a characteristic fall in BP during sleep. 23 It is now well-recognised that this nocturnal decline in BP is blunted following heart transplantation and may indeed disappear completely. This may provide insight both into mechanisms for the hypertension as well as some of the complications which occur after transplantation. 24 In a non-invasive ambulatory BP monitoring study of 34 cardiac transplant recipients, 50% did not show the normal nocturnal decline in BP, and 25% had predominantly nocturnal hypertension. 25 This lack of decline in nocturnal BP is seen in normotensive as well as in hypertensive patients. 26 Several mechanisms have been suggested. Of interest, patients with conditions causing autonomic neuropathy, such as diabetes mellitus, also develop this abnormal nocturnal BP pattern. 27 Thus loss of cardiac innervation could be one mechanism, resulting from impairment of afferent and efferent baroreceptor reflexes. A resulting failure to decrease heart rate and to vasodilate in response to the increase in central volume and filling pressure with the supine posture during sleep may contribute to the failure of BP to decrease normally at night.
One test of the importance of this mechanism is to examine whether the day-night BP difference becomes more normal with time after transplant as functionally significant re-innervation of the donor heart develops. [28] [29] [30] [31] [32] [33] If denervation is a major mechanism, and functionally significant re-innervation does occur, then the day-night BP profile should return to normal. In a cross-sectional study, van de Borne et al 34 reported re-appearance of a more normal circadian rhythm of BP by 7 months after trans-plant. This appears likely to be too early to be explained by functional re-innervation and in fact was attributed by the authors to a decrease in the dose of glucocorticoids for immunosuppression. 34 Another possible explanation is the reduction in cyclosporin dose and trough plasma level which is normal practice at this stage. Bracht and colleagues 35 noted a loss of nocturnal fall in heart rate and BP early (Ͻ6 months) after transplant in 30 patients, with an improvement in circadian changes in a second group of 32 patients late (7-78 months) after transplant. They postulated that the difference could be related to partial cardiac re-innervation. In contrast, Idema et al 36 in a further cross-sectional study reported that decreased circadian BP variation persists for up to 36 months after transplant. In a crosssectional study in 27 patients in whom 24-h BP recordings were obtained from 1 to 11 years after transplant, there was no significant association between time after transplant and day-night decrease in BP. 124 In a small prospective study, Khot and colleagues, 37 looked at eight patients early and at 2 years following cardiac transplantation and found restoration of a diurnal rhythm in some patients.
In a further cross-sectional study of 11 cardiac transplant recipients using MIBG scintigraphy to produce an index of cardiac sympathetic efferent reinnervation, no association was found between the index of re-innervation and absolute BP or diurnal BP variation. 38 Sympathetic cardiac efferent reinnervation may have little functional effect, or alternatively, the cardiac parasympathetic nerves may have a more significant role in lowering BP at night.
Studies in renal transplant recipients also suggest that mechanisms other than loss of cardiac innervation appear to be important in explaining the abnormal diurnal BP variation. In renal transplant recipients, Hohage et al 39 showed that there was a lack of nocturnal decline in BP in about 60% of patients, and that the actual nocturnal change in BP was similar in cyclosporin and tacrolimus treated groups. In a further study in renal transplant recipients, van den Dorpel et al 40 looked at ambulatory BP before and 16 weeks after conversion from cyclosporin to azathioprine immunosuppression. Following conversion, there was a fall in BP, an increased nocturnal fall in BP, a reduction in the number of 'nondippers', and a decrease in plasma ANP. These studies suggest that cyclosporin and tacrolimus are significantly involved in the hypertension and abnormal BP profile seen after transplantation. 40 However, in a study of 10 kidney-pancreas transplant recipients, a marked increase in nocturnal BP, up to 25% greater than the daytime pressure was found, and no relationship was demonstrated with the immunosuppression regimen. 41 Bunke and colleagues 42 showed that once daily (morning) vs twice daily cyclosporin dosing (same total daily dose) reduced nocturnal BP, improved glomerular filtration rate (inulin clearance) and improved the lipid profile. The long-term effects on graft survival of such a regimen are yet to be tested. 42 The clinical implications of the blunted nocturnal BP fall are significant. Because BP fails to decrease normally at night in heart transplant patients, total daily BP load is greater for a given level of clinic pressure than in subjects with essential hypertension. Thus BP-linked complications in heart transplant patients may be greater than expected from clinic readings. 22 The role of ambulatory BP monitoring in assessing hypertension in cardiac transplant recipients has been stressed, 25 however thresholds of treatment and aims of treatment in terms of absolute level of BP and restoration of the normal circadian BP pattern have not been well defined. Cugini et al 43 looked at 34 cardiac transplant recipients and found that 7/9 of those labelled as normotensive were hypertensive based on their ambulatory BP monitoring criteria, and 17/25 considered hypertensive were poorly controlled on their current drug treatment. It is as yet unclear whether there is any benefit from treating hypertension in these patients in such a way as to attempt to restore the normal 24-h BP profile. Angerman et al 44 found that treating cardiac transplant recipients in a normal manner with a combination of enalapril, frusemide ± verapamil lowered the BP level effectively, but did not influence the circadian pattern.
Sodium balance and extracellular fluid volume
Sodium intake is a major determinant of extra-cellular volume in normal man. Considerable evidence links dietary sodium intake to the development of essential hypertension. There is now increasing interest in the role of dietary sodium in the development of hypertension after heart transplantation. In heart transplant patients there is clear evidence for a defect in regulation of salt and water balance. 45 Plasma levels of the cardiac hormone atrial natriuretic peptide are an index of central blood volume, levels of atrial natriuretic peptide (ANP) increasing under conditions of central volume expansion. Levels of plasma ANP are markedly increased in heart transplant patients. [46] [47] [48] There are several factors underlying these higher levels of ANP, however, one explanation is that the increase is in part a marker of central volume expansion, confirmed by Braith's study showing that plasma volume is increased. 49 In one study, 50 mean 24-h plasma ANP was elevated by a mean of 44% in normotensive and 190% in hypertensive heart transplant recipients compared to healthy controls. It was suggested that raised levels of ANP were a compensatory mechanism to antagonise high BP. 50 In hypertensive renal transplant recipients, Hestin et al 51 found a positive correlation between plasma ANP and BP. This was not seen in normotensive renal transplant recipients. 51 A further suggestion is that left and right atrial dysfunction relating to the recipient-donor anastomosis, which has been demonstrated by cine MRI studies in these patients, 52 may be partly responsible for the elevated ANP levels. Geny and colleagues, 53 however, looked at 'atrial ejection force', defined as the force exerted by the left atrium to accelerate blood into the left ventricle during atrial systole, by 2D imaging and Doppler echocardiography. They found that although the atrial area was greater in cardiac transplant recipients, there was no signifi-cant correlation between the atrial ejection force and plasma ANP in cardiac transplant recipients or in controls. 53 Secondly BP in heart transplant patients is salt sensitive, with a clinically important decrease in BP on short term reduction in sodium intake, in contrast to the BP response in normal subjects. 45 The mechanisms for this defect in the regulation of sodium balance are unclear. Cyclosporin A treatment appears implicated as a contributory factor, as when sodium intake was decreased in renal transplant recipients, BP decreased in patients on cyclosporin A but not in those on azathioprine. 54 A defect in sensing and responding to changes in central volume resulting from cardiac denervation could also result in abnormal regulation of sodium and water balance. 45 Blunted excretion of sodium could contribute to the increased plasma volume reported by Bellet 55 and Braith 49 resulting in a diminished day-night difference in central blood volume. Braith et al 49 reported a 14% increase in extracellular fluid volume in cardiac transplant recipients who became hypertensive, which was not seen in liver transplant recipients or controls. They suggested that a lack of responsiveness of the reninangiotensin system to a hypervolaemic stimulus, possibly related to cardiac de-afferentation, was responsible for the increased extracellular fluid volume, and the high prevalence of hypertension in these patients. 49 Braith and colleagues, in a further study, 56 looked at the responses to an acute intravenous sodium load in cardiac transplant recipients, liver transplant recipients and normal controls. They found that the cardiac transplant recipients had a blunted natriuretic and diuretic response to a sodium load and failed to suppress fluid regulatory hormones. This was not seen in liver transplant recipients taking cyclosporin, and thus could not be attributed to cyclosporin alone. A loss of cardiorenal neuroendocrine reflexes secondary to cardiac de-innervation was postulated as a mechanism.
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Renal impairment following transplantation
Mild to moderate renal impairment frequently develops in heart transplant recipients and may thus also be important in post-transplant hypertension, directly because of tubular dysfunction and indirectly by activation of the renin-angiotensin system. However renal impairment does not appear to play a major role. In the study by Ozdogan et al, 16 those with a serum creatinine greater than 120 mol/l had only a 5-8% higher incidence of hypertension during the first 4 years after heart transplantation than those with a lower creatinine. It is noted that in experimental models in animals, dietary salt restriction, which is recommended in humans as non-pharmacological management of hypertension, can increase the nephrotoxicity of cyclosporin and tacrolimus. 57 
Hypertension and resistance arteries following transplantation
Small arteries make a major contribution to systemic vascular resistance. Using small artery myography, remodelling and structural abnormalities have been reported in patients with essential hypertension. 58 An intriguing hypothesis is that vascular changes in resistance arteries may also be important in posttransplant hypertension. One attractive concept is that vasoconstriction of small arteries occurs as a compensatory mechanism for low cardiac output in end-stage heart failure to maintain arterial pressure. Candidate mediators include high levels of catecholamines and a defect in the nitric oxide (NO)-pathway. Increased levels of growth factors in heart failure, eg, angiotensin II 59 and decreased levels of the growth inhibitor, transforming growth factor-1 60 could also contribute to an increase in vascular structure, leading to increased wall:lumen ratio. With a new donor heart producing a more normal cardiac output, peripheral vessels would thus not be able to undergo adequate homeostatic vasodilatation. This would result in a sustained increase in systemic vascular resistance and a predisposition to hypertension.
There is also a correlation between serum cyclosporin A levels and mean artery wall thickness. 61 Initial structural abnormalities in small arteries could be one mechanism on which post-transplant amplification may act. Initial increases in small artery structure could be exacerbated by the stimulatory effects of increased expression of growth factors after transplantation. Cardiovascular growth factors which may be released in response to the cyclosporin treatment include angiotensin II 62 and endothelin-1. 63 Evidence for this has come from studies by Cavero et al 64 who reported that forearm vascular resistance initially improves with heart transplantation and then increases towards the higher level of arterial resistance present in patients with severe heart failure.
Support for this comes from a recent morphometric analysis of cardiac transplant endomyocardial biopsy specimens showing correlation between BP, particularly diastolic BP and the rate of medial thickening of intramyocardial resistance arteries and arterioles. 61 
Immunosuppressant therapy and hypertension
A Cyclosporin A
The advent of cyclosporin immunosuppression resulted in a dramatic increase in graft survival following cardiac transplantation to around 81% at 1 year then 4% annual mortality up to 12 years after transplant. 65 However there are a number of clinically significant side effects of cyclosporin. The predictable side effects of immunosuppression, opportunistic infections and malignancy are welldescribed. 6, 7 Patients given cyclosporin have a higher incidence of hypertension than those on other immunosuppressive therapy. 14, 16 Mechanisms include direct vasoconstriction, stimulation of vasoconstrictor hormones, reduced activity of vasodilator pathways, increased sympathetic nervous system activity, and effects of renal impairment.
Cyclosporin and vasoconstriction:
Infusion of cyclosporin into isolated canine arteries causes vasoconstriction which results in an increased vascular resistance and thus higher BP. 66 This vasoconstriction can be inhibited by a calcium antagonist but is not modified by alpha-adrenoreceptor blockade, sympathectomy, thromboxane receptor antagonists or acetyl-choline. 66 The highly potent, endothelium-derived constricting peptide endothelin-1 67 is an important candidate for vasoconstriction caused by cyclosporin, and may be implicated in both hypertension and nephrotoxicity. 68 Increased levels of urinary and circulating endothelin have been described in cyclosporin-treated humans and animals. 68 Cyclosporin has been reported in culture studies to stimulate expression of endothelin-1 from human renal proximal tubular cells. 63 Secondly, the vasoconstrictor effects of endothelin-1 are associated with influx of calcium into cells which can be inhibited by pretreatment with a calcium antagonist. 69 Further evidence linking cyclosporin and endothelins was obtained by Grieff et al 70 who found that a rise in endothelin-1, maximal at 6 hours, follows the increase in blood levels of cyclosporin and its metabolites after acute treatment with cyclosporin. This response was exaggerated in those with longterm grafts. 70 Bloom and colleagues 71 looked at renal afferent and efferent arteriolar dimensions in hydronephrotic rats. Cyclosporin constricted the whole of the renal microvasculature, whereas L-NAME (nitric oxide synthase inhibitor) preferentially constricted the afferent vessels. l-arginine reversed the effects of cyclosporin on renal microvasculature. They concluded that preglomerular basal vascular tone was dependent on continuous production of NO and alterations in the l-arginine-NO pathway contribute to cyclosporin-induced renal vasoconstriction. 71 Bartholomeusz et al 72 showed that bosentan, a non-peptide endothelin receptor antagonist, lowered BP in cyclosporin-treated rats, but not in controls, adding weight to this hypothesis.
Cyclosporin and vasodilator activity:
A decrease in levels of the endothelial-derived relaxing factor nitric oxide has been implicated in cyclosporinmediated hypertension. 73, 74 Marumo and colleagues 75 however also showed that cyclosporin A inhibited inducible nitric oxide synthase activity in rat aortic smooth muscle cells. Administration of larginine to spontaneously hypertensive rats protects against the pressor effects of cyclosporin. 73, 74 Cyclosporin and the sympathetic nervous system: There is controversy about effects of cyclosporin on the sympathetic nervous system. This may partly arise from species differences in responses to cyclosporin treatment. During infusion of cyclosporin to anaesthetised rats, there is a dose-dependent increase in vascular resistance, arterial pressure and renal and lumber sympathetic nerve activity which is greatly attenuated by alpha-adrenergic receptor blockade. 76 In a further study, Grobecker et al 77 showed that cyclosporin increases BP in spontaneously hypertensive rats and genetically related normotensive Wistar-Kyoto rats after both single IV and long term oral administration. Chemical sympathectomy with 6-hydroxydopamine, depletion of catecholamine stores with reserpine, or alpha-1 adrenergic blockade with prazosin blunted this hypertensive response suggesting sympatho-adrenal activation by cyclosporin as a mechanism. 77 The mechanism of sympathetic activation by cyclosporin in rats seems to be in common with tacrolimus. 78 In studies in man, Scherrer et al 79 also reported evidence for sympathetic activation by cyclosporin. In heart transplant patients treated with cyclosporin they found higher BP, 50% higher plasma noradrenaline levels and increased firing rates in sympathetic fibres in the peroneal nerve compared to cardiac transplant recipients treated with prednisolone and azathioprine. 79 In contrast, Kaye et al 80 measured renal blood flow, forearm blood flow, whole-body radiolabelled noradrenaline kinetics and peroneal muscle sympathetic nerve firing in cardiac transplant recipients on cyclosporin A and healthy volunteers. They concluded that cyclosporin causes acute non-neural renal vasoconstriction, not attributable to sympathoexcitation, without accompanying systemic haemodynamic changes. 80 In a more recent study, Rundqvist et al 81 showed that the augmented regional sympathetic output to the kidney and skeletal muscle beds in heart failure, measured using isotope dilution with steady state infusions of [3H]Noradrenaline, was comparable in heart transplant recipients on cyclosporin to healthy volunteers. They compared transplant recipients on cyclosporin A with healthy controls, and did not support the concept that cyclosporin-induced hypertension is mediated by cyclosporin-induced increased sympathetic nerve activity. 81 In a longitudinal study, the same group looked at intraneural recordings of muscle sympathetic nerve activity repeatedly before and during the first year after cardiac transplantation. One month following transplant there was a significant reduction in muscle sympathetic burst frequency (35%) and burst incidence (32%) compared to the high levels pre transplant, and this did not change further up to 1 year following transplantation. The reduction was similar in those patients who became hypertensive compared to those who were normotensive following transplantation. 82 Andreassen and colleagues 83 used the Valsalva manoeuvre and cold pressor test to stimulate sympathetic neural outflow and a vasodilator test that is dependent on the presence of a functionally intact endothelium (postocclusive hyperaemia) in 16 cardiac transplant and matched healthy controls. They found endothelial dysfunction in transplant recipients on cyclosporin with intact functional capacity of the sympathetic nervous system. 83 Thus, unlike in animal studies, there is no consistent evidence for increased sympathetic nervous activity in cardiac transplant recipients on cyclosporin A.
Cyclosporin and the kidneys: Renal haemodynamics can be impaired by direct or indirect vasoconstrictor effects of cyclosporin. Intravenous infusion of cyclosporin causes an immediate reduction in renal blood flow 84 and glomerular filtration rate resulting from vasoconstriction of the glomerular afferent arteriole. 85 There is evidence that this renal afferent arteriolar constriction may be mediated by an imbalance between vasoconstrictors (eg, endothelin-1) and vasodilator hormones (eg, prostaglandins 86 ). A further mechanism is that cyclosporin also increases the sensitivity of the glomerular afferent arteriole to the vasoconstrictors noradrenaline, angiotensin II and anti-diuretic hormone. 85 Ischaemia of the juxta-glomerular apparatus results in angiotensin II-mediated systemic vasoconstriction and angiotensin II and aldosteronemediated sodium reabsorption. Secondly, there may be additional sodium and water retention as a result of direct, cyclosporin-induced tubular damage. Cyclosporin A may cause renal mediated hypertension by both these mechanisms by acute and by chronic effects.
Patients on long-term cyclosporin treatment typically have mild-to-moderate chronic renal impairment. [87] [88] [89] Late reduction in the dose of cyclosporin does not appear to improve the renal function and is associated with an increased incidence of acute rejection. 87, 88 Two major candidate mechanisms are a direct toxic effect of cyclosporin on the renal tubules 88 and indirect renal damage because of vasoconstriction-mediated ischaemia. 66 Histological changes in the kidney are well defined, there being a progressive increase in renal arteriolar hyalinosis and percentage of glomeruli demonstrating global sclerosis with time of exposure and also with total cumulative dose of cyclosporin. 90 In one small study there was no significant association between the severity of renal pathologic change and systemic BP level or serum creatinine. 90 Rarely, cyclosporin may cause a thrombotic micro-angiopathy similar to the haemolytic uraemic syndrome. Renal biopsies in affected patients show mesangial sclerosis, severe tubulo-interstitial inflammation and occlusion of renal arterioles and glomeruli by micro-thrombi. 85 Ader et al 91 showed that cardiac transplant recipients have a reduced baseline GFR and reduced renal functional reserve (per kidney) when compared to renal transplant recipients. They attributed the difference to higher cyclosporin levels, activation of intact renal sympathetic nerves, cardiac de-innervation, renal consequences of former heart failure, and higher prevalence of hypertension in heart transplant recipients. 91 Cyclosporin and the renin-angiotensin system: There is debate on the degree to which stimulation of the renin-angiotensin is important in cyclosporin-mediated hypertension in man. In a crosssectional study of 21 cardiac and 12 liver transplant recipients on cyclosporin, supine and upright plasma renin activity tended to be higher and total, active, and inactive plasma renin activity was higher than in controls. 62 However an important confounding factor was that the transplant patients had a relatively low sodium intake, a potent stimulus for renin release. Bantle and colleagues 92 found that plasma renin activity was suppressed in cardiac transplant recipients, but could be stimulated by a 4-day period of dietary sodium restriction and diuretic administration. They concluded that suppression of plasma renin activity by cyclosporin is physiologic and may reflect expansion of extracellular fluid volume, which can be reversed by sodium depletion.
In a separate study in 10 heart transplant patients, Sehested et al 93 found that blood samples taken after their usual dose of cyclosporin did not reveal significant acute effects on plasma noradrenaline, renin activity, aldosterone, atrial natriuretic peptide, calcitonin-gene related peptide, endothelin or vasopressin. 93 In a further study, Bellet et al 55 looked at 15 cardiac transplant recipients on cyclosporin under standardised conditions, and found a 15% increase in plasma volume, but normal levels of plasma renin activity, aldosterone, angiotensinogen and angiotensin-converting enzyme.
Neoral cyclosporin: Neoral (Novartis) is a new microemulsion formulation of cyclosporin recently available which may have some advantages over conventional Sandimmune cyclosporin. In one study of conversion from Sandimmune to Neoral cyclosporin in 20 heart transplant recipients, Neoral resulted in a 24% greater exposure to cyclosporin compared with Sandimmune despite similar trough levels. 94 BP readings increased in 20% of patients previously known to be hypertensive. Ambulatory BP monitoring revealed a reduced nocturnal drop in systolic pressure on Neoral compared to Sandimmune. 94 In a second study, there appeared to be no difference in the effect on diastolic BP between Sandimmune or Neoral, after corrections for differences in exposure to the drugs had been taken into account.
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B Tacrolimus (FK506)
This more recently introduced penicillin-like macrolide immunosuppressant, which has a similar mode of action to cyclosporin A, 10,96 also causes hypertension and renal impairment. 57, 89, 97 In some circumstances it appears to have improved immunosuppressive actions compared to conventional cyclosporin. The prevalence of hypertension with FK 506 appears lower than with cyclosporin, but differs markedly between studies. Possible reasons for variation include differences in age, steroid-sparing, organ transplanted, small groups, non-standardised time after transplantation, the use of historical comparisons and non-standardised methods of assessing BP.
The mechanisms of tacrolimus-associated hypertension remain to be fully elucidated, but are believed to be similar to that of cyclosporin. 10 Shortterm infusion of tacrolimus into pigs produced elevation of BP without any major changes in renal function. 98 Tacrolimus infusion into normotensive rats produced hypertension which could be blunted by the calcium channel blocker felodipine. 77 Both tacrolimus and cyclosporin appear to cause hypertension in rats via sympathetic activation mediated by extralymphoid calcineurin-mediated pathways. 78 Takeda et al 99 however showed that tacrolimus also causes upregulation of the ET(A) receptor in rat vasculature, which may contribute to the genesis of hypertension.
In a paediatric heart transplant population, hypertension on tacrolimus was not seen in the absence of renal impairment or steroid therapy. 100 In a further study 5/6 hypertensive paediatric cardiac transplant recipients switched from cyclosporin to tacrolimus discontinued antihypertensives. 101 In 66 paediatric cardiac transplant recipients, Armitage et al 102 found the prevalence of post-transplant hypertension was 4% in tacrolimus treated and 70% in cyclosporin treated patients. In 31 paediatric liver transplant patients, six out of eight patients noted to be hypertensive on cyclosporin and prednisolone showed resolution of hypertension after conversion to tacrolimus. 103 In paediatric renal transplants, a low level of hypertension was noted on tacrolimus. 104 In a randomised study of cyclosporin vs tacrolimus immunosuppression in 243 adult cardiac transplant recipients, 47% in the tacrolimus group compared to 84% in the cyclosporin group were hypertensive. There was, however, greater steroid usage in the cyclosporin group. 105 A further randomised study of 25 patients showed a lower prevalence and severity of hypertension in a tacrolimus treated group, but again there were differences in steroid usage. 106 A lower incidence of hypertension was noted in an adult liver transplant population. 107 In the 2-year follow-up data of the European multicentre tacrolimus liver study, hypertension was less common in the tacrolimus (28%) when compared to the cyclosporin (40%) treated group. 108 Textor found than 4 months after liver transplantation, 4/14 (28%) of liver transplant patients treated with tacrolimus and prednisolone developed hypertension compared to 25/32 (78%) in a group treated with cyclosporin and prednisolone. 109 In contrast, McDiarmid in comparison found no significant difference in the BP of two groups of 90-day survivors or liver transplantation who were taking cyclosporin or tacrolimus.
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C Corticosteroids
In some centres, steroid treatment is reserved for the immediate post-transplant period or used as part of short term treatment for episodes of rejection. In such centres, only a minority of patients, eg, those with significant renal impairment and in whom adequate cyclosporin levels cannot be achieved, receive chronic steroid immunosuppression. Increasingly, there is a trend towards routine steroid immunosuppression for the first 6 to 12 months following transplantation. Steroid therapy may contribute directly to post-transplant clinic and nocturnal hypertension.
34 In Ozdogan's study, 16 steroid exposure during the first year following transplantation did not correlate with the presence of hypertension at 1 year. In a further study, withdrawal of prednisolone from triple immunosuppression therapy consisting of cyclosporin, azathioprine and prednisolone by 6 months post-transplant did not significantly reduce BP compared to those maintained on triple therapy. 111 It is however possible that short-term steroid treatment could be an initiating factor for changes which, with amplification by vasoconstrictors and growth factors, could contribute to the increasing prevalence of hypertension later after transplantation. Taler and colleagues 112 looked at liver transplant recipients 4 months after transplantation immunosuppressed with either tacrolimus and low dose steroids, tacrolimus and high dose steroids or cyclosporin and high dose steroids and found a prevalence of hypertension of 32%, 63% and 85% respectively. 112 This suggested a central role for steroid dose in the etiology of onset of hypertension early after liver transplantation using tacrolimus immunosuppression. 112 Of interest, abnormal steroid metabolism 113 has been implicated as a factor in the link between early events in utero and later hypertension and cardiovascular disease.
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Hypertension and allograft left ventricular hypertrophy
Left ventricular hypertrophy, independent of hypertension, is a significant risk factor for cardiovascular disease. Left ventricular hypertrophy develops with time after transplant 114, 115 and is not fully explained by the development of hypertension. Indeed Julien et al 116 reported little evidence for any role of hypertension in the occurrence of left ventricular hypertrophy in the early months after transplant. However they did not measure 24-h BP and therefore did not take into account loss of nocturnal decrease in BP in these patients. 116 There is increasing interest in the functional impact of the cardiac re-innervation which is known to occur following transplantation on the risk of cardiovascular complications after transplant. [28] [29] [30] 32, 33, 48 Cardiac hypertrophy occurs in experimental animal models of denervation. 117 Cardiac hypertrophy is also a feature of transgenic animals in whom the adrenergic receptors are over-expressed. 118 Thus cardiac denervation may interact with hypertension to increase left ventricular hypertrophy after transplantation and functional re-innervation of the heart could help to allow its regression. In a study of cardiac sympathetic re-innervation using MIBG scintigraphy, no significant association was found between left ventricular mass index and the index of reinnervation. 38 A further mechanism for post-transplant left ventricular (LV) hypertrophy may be effects of cyclosporin to stimulate cardiac growth factors, altering the normal homeostasis of cardiac tissue turnover. 119 One study used short axis cine MRI imaging to look at the left ventricle 2 months after cardiac transplant and found an increase in LV mass but normal volume and ejection fraction compared to controls. 120 In this study there was a significant correlation between LV mass and cyclosporin level, but no correlation with BP, ischaemic time, acute rejection episodes, age, body mass, plasma catecholamines or plasma renin activity. 120 The clinical importance of left ventricular hypertrophy following cardiac transplantation is unclear, and it does not necessarily have the same prognostic importance as in essential hypertension.
Other causes of hypertension
Potentially reversible as well as pre-existing or new secondary causes of hypertension should also be considered. These include renal parenchymal disease and endocrine mechanisms such as primary hyperaldosteronism, primary hyperparathyroidism, phaeochromocytoma, thyroid disease, acromegaly and Cushing's disease. In addition, heart transplant patients have risk factors for atheromatous vascular disease and are thus at increased risk of reno-vascular disease as a cause of hypertension.
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Hypertension and cardiac allograft vasculopathy
Two single-centre studies have reported associations between post-transplant hypertension and the development of cardiac allograft vasculopathy.
Arbustini et al, 122 in a multivariate analysis in 257 patients, showed that hypertension was a risk factor for the development of allograft vascular disease with odds ratio 2.2. Barbir and colleagues 123 showed that in a multivariate logistic regression analysis, hypertension was a predictor of the development of coronary calcification on ultrafast CT, a marker of coronary artery disease in the transplanted heart.
